

Curriculum Vitae

Personal information Teresa Amaral

Work experience

Current position:

Head of the Skin Cancer Clinical Trials Center University of Tübingen, Germany

2022-current Principal Investigator/Deputy and Sub-investigator (SI) in > 20 trials
2022-current Lecturer at the Tuebingen University, Germany, UBI Beira Interior University and Porto University, Portugal

2021-current Clinical Lead Translational Research Dermato-Oncology Department

2018-current Medical Lead Biobank Dermato-Oncology Department

2013 Lecturer at the Lisbon University Medicine Master's program

2012-2013 Lecturer at the Coimbra University Medicine PhD program

2013 European Society of Medical Oncology (ESMO) Medical Oncology Examination Amsterdam

2012 3 months fellowship at Skin Cancer Center Tuebingen

2008-2014 SI in clinical trials: skin cancer and ovarian cancer – Hospital Center Lisbon North (CHLN) Lisbon

2008-2014 Medical Oncology Internship – CHLN

2008-2009 Collaboration with Evidence Based Medicine Study Center – Lisbon (Centro de Estudos de Medicina Baseados na Evidência (CEMBE))

2006-2008 General Internship - General Training in Internal Medicine, General Surgery, Gynecology, Pediatrics and Primary Care Medicine – CHLN

2002-2003 Invited Teacher for normal anatomy and neuroanatomy – Medicine Faculty Lisbon University

Education and training

2022 Board Certificate - Internal medicine, Hematology and Oncology – German Medical Association

2018 German Approbation at Medical Association of Baden-Württemberg (Ärztekammer Baden-Württemberg)

2014 Board certificate - Medical Oncology – Portuguese Medical Association

2000-2006 Medical Degree – Medicine Faculty Lisbon University and Portuguese Air Force Academy

Additional information

Publications

Publications list (stand 30.11.2024)

Items 1-103 of 103 (Display the 103 citations in PubMed)

1. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Couselo EM, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA; ESMO Guidelines Committee.

Ann Oncol. 2024 Nov 13:S0923-7534(24)04912-3. doi: 10.1016/j.annonc.2024.11.006. Online ahead of print. PMID: 39550033 No abstract available.

2. Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.

McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, de Lima Vazquez V, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Abrão Possik P, Robles Espinoza CD, Ito F, In GK. Br J Dermatol. 2024 Oct 23:ljae401. doi: 10.1093/bjd/ljae401. Online ahead of print. PMID: 39438074

3. Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group.

Loh KP, Liposits G, Arora SP, Neuendorff NR, Gomes F, Krok-Schoen JL, Amaral T, Mariamidze E, Biganzoli L, Brain E, Baldini C, Battisti NML, Frélaud M, Kanesvaran R, Mislav ARA, Papamichael D, Steer C, Rostoft S.

ESMO Open. 2024 Aug;9(8):103657. doi: 10.1016/j.esmoop.2024.103657. Epub 2024 Aug 19. PMID: 39232585 Free PMC article. Review.

4. Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021.

Wiens L, Grözinger G, Dittmann H, Thiel K, Leiter U, Amaral T, Nanz L, Flatz L, Forscher A. Ther Adv Med Oncol. 2024 Aug 23;16:17588359241273020. doi: 10.1177/17588359241273020. eCollection 2024.

PMID: 39184023 Free PMC article.

5. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors?

Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, Eigentler TK, Amaral T, Moltz JH, Othman AE. Cancers (Basel). 2024 Jul 26;16(15):2669. doi: 10.3390/cancers16152669. PMID: 39123397 Free PMC article.

6. Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV

melanoma: a multicenter international study.
 Chatzioannou E, Higuera LMS, Kreft S, Kandolf L, Dujovic B, Reinhardt L, Tamara E, Marquez-Rodas I, Fortuna ARFP, Nübling A, Niessner H, Forschner A, Garbe C, Popovic A, Mirjana B, Meier F, Eigentler T, Leiter U, Flatz L, Sinnberg T, Amaral T. ESMO Open. 2024 Aug;9(8):103661. doi: 10.1016/j.esmoop.2024.103661. Epub 2024 Aug 2. PMID: 39096893 Free PMC article.

7. Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition.
 Forschner A, Nanz L, Maczey-Leber Y, Amaral T, Flatz L, Leiter U.
 Int J Cancer. 2025 Jan 1;156(1):145-153. doi: 10.1002/ijc.35103. Epub 2024 Jul 20. PMID: 39032035

8. Improving assessment of lesions in longitudinal CT scans: a bi-institutional reader study on an AI-assisted registration and volumetric segmentation workflow.
 Hering A, Westphal M, Gerken A, Almansour H, Maurer M, Geisler B, Kohlbrandt T, Eigentler T, Amaral T, Lessmann N, Gatidis S, Hahn H, Nikolaou K, Othman A, Moltz J, Peisen F. Int J Comput Assist Radiol Surg. 2024 Sep;19(9):1689-1697. doi: 10.1007/s11548-024-03181-4. Epub 2024 May 30. PMID: 38814528 Free PMC article.

9. Exploring 'decision regret' in adjuvant-treated melanoma patients: Results from a cross-sectional survey on 200 participants.
 Grünke T, Reiter S, Meyer S, Graf J, Schaeffeler N, Leiter U, Amaral T, Flatz L, Forschner A. J Eur Acad Dermatol Venereol. 2024 May 19. doi: 10.1111/jdv.20105. Online ahead of print. PMID: 38764366 No abstract available.

10. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
 Garbe C, Forsea AM, Amaral T, Arenberger P, Autier P, Berwick M, Boonen B, Bylaite M, Del Marmol V, Dreno B, Fargnoli MC, Geller AC, Green AC, Greinert R, Hauschild A, Harwood CA, Hoorens I, Kandolf L, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Lim HW, Longo C, Malvey J, Moreno D, Pellacani G, Peris K, Robert C, Saiag P, Schadendorf D, Peter Soyer H, Stockfleth E, Stratigos A, Uhara H, Vieira R, Volkmer B, Weinstock MA, Whitaker D, Zalaudek I, Whiteman DC, Brochez L. Eur J Cancer. 2024 Jun;204:114074. doi: 10.1016/j.ejca.2024.114074. Epub 2024 Apr 24. PMID: 38691877 Review.

11. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
 Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L. Eur J Cancer. 2024 May;203:114028. doi: 10.1016/j.ejca.2024.114028. Epub 2024 Mar 27. PMID: 38652976

12. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
 Wyss N, Berner F, Walter V, Jochum AK, Purde MT, Abdou MT, Sinnberg T, Hofmeister K, Pop OT, Hasan Ali O, Bauer J, Cheng HW, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer BS, Driessen C, Schürch CM, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy AN, Schneider T, Brutsche MH, Sette A, Lenz TL, Walz J, Rammensee HG, Früh M, Jäger E, Becher B, Tufman A, Nuñez N, Joergers M, Flatz L. Am J Respir Crit Care Med. 2024 Oct 1;210(7):919-930. doi: 10.1164/rccm.202311-2136OC. PMID: 38626354

13. Multidisciplinary approach and treatment of acral and mucosal melanoma.
 Fortuna A, Amaral T. Front Oncol. 2024 Feb 26;14:1340408. doi: 10.3389/fonc.2024.1340408. eCollection 2024. PMID: 38469235 Free PMC article. Review.

14. Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB.
 Amaral T, Nanz L, Stadler R, Berking C, Ulmer A, Forschner A, Meiwes A, Wolfspurger F, Meraz-Torres F, Chatzioannou E, Martus P, Flatz L, Garbe C, Leiter U. Eur J Cancer. 2024 Apr;201:113912. doi: 10.1016/j.ejca.2024.113912. Epub 2024 Feb 10. PMID: 38368742

15. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.
 Meraz-Torres F, Niessner H, Plöger S, Riel S, Schörg B, Casadei N, Kneilling M, Schaller M, Flatz L, Macek B, Eigentler T, Rieß O, Garbe C, Amaral T, Sinnberg T. J Exp Clin Cancer Res. 2024 Jan 23;43(1):30. doi: 10.1186/s13046-023-02941-5. PMID: 38263136 Free PMC article.

16. Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017.
 Reitmajer M, Leiter U, Nanz L, Amaral T, Flatz L, Garbe C, Forschner A.
 J Cancer Res Clin Oncol. 2024 Jan 18;150(1):15. doi: 10.1007/s00432-023-05533-0. PMID: 38238578 Free PMC article.

17. Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
 Peisen F, Gerken A, Dahm I, Nikolaou K, Eigentler T, Amaral T, Moltz JH, Othman AE, Gatidis S. PLoS One. 2024 Jan 5;19(1):e0296253. doi: 10.1371/journal.pone.0296253. eCollection 2024. PMID: 38180971 Free PMC article.

18. Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma.
 Nübel C, Amaral T, Leiter U, Flatz L, Forschner A. Front Oncol. 2023 Nov 30;13:1256800. doi: 10.3389/fonc.2023.1256800. eCollection 2023. PMID: 38098509 Free PMC article.

19. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study.
 Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler TK, Forchhammer S, Flatz L. J Am Acad Dermatol. 2024 Apr;90(4):739-748. doi: 10.1016/j.jaad.2023.11.040. Epub 2023 Dec 1. PMID: 38043594

20. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
 Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L.
 Eur J Cancer. 2024 Jan;196:113425. doi: 10.1016/j.ejca.2023.113425. Epub 2023 Nov 21. PMID: 38039778

21. [S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 2: Epidemiologie und Ätiologie, Diagnostik, Therapie des invasiven Plattenepithelkarzinoms der Haut, Nachsorge und Prävention: S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention].
 Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenbergh C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. J Dtsch Dermatol Ges. 2023 Nov;21(11):1422-1434. doi: 10.1111/ddg.15256_g. PMID: 37946644 German.

22. Response to the letter entitled 'On finding acceptance'.
 Lim KHJ, Westphalen CB, Mateo J, Lambertini M, Amaral T. ESMO Open. 2023 Dec;8(6):102059. doi: 10.1016/j.esmoop.2023.102059. Epub 2023 Nov 3. PMID: 37925847 Free PMC article. No abstract available.

23. Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study.
 Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, Eigentler TK, Amaral T, Moltz JH, Othman AE. Diagnostics (Basel). 2023 Oct 14;13(20):3210. doi: 10.3390/diagnostics13203210. PMID: 37892030 Free PMC article.

24. S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care.

Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberger C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. J Dtsch Dermatol Ges. 2023 Oct;21(10):1249-1262. doi: 10.1111/ddg.15231. PMID: 37845077

25.[Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab]. Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A. J Dtsch Dermatol Ges. 2023 Oct;21(10):1137-1147. doi: 10.1111/ddg.15164. g. PMID: 37845056 German.

26.[S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen: S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care]. Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberger C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. J Dtsch Dermatol Ges. 2023 Oct;21(10):1249-1262. doi: 10.1111/ddg.15231. g. PMID: 37845050 German.

27.S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, ElGammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberger C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. J Dtsch Dermatol Ges. 2023 Nov;21(11):1422-1433. doi: 10.1111/ddg.15256. Epub 2023 Oct 15. PMID: 37840404

28.Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain. Roitberg F, Amaral T, Cherny NI, Giuliani R, Latino NJ, Galotti M, Bricalli G, Curigliano G, Pentheroudakis G, Trapani D. ESMO Open. 2023 Oct;8(5):101617. doi: 10.1016/j.esmoop.2023.101617. Epub 2023 Sep 4. PMID: 37672862 Free PMC article.

29.Young oncologists' perspective on the role and future of the clinician-scientist in oncology. Lim KHJ, Westphalen CB, Berghoff AS, Cardone C, Connolly EA, Güven DC, Kfoury M, Kocakavuk E, Mandó P, Mariamidze E, Matikas A, Moutafi M, Qing C, Pihlak R, Punie K, Sánchez-Bayona R, Sobczuk P, Starzer AM, Tečić Vuger A, Zhu H, Cruz-Ordinario MVB, Altuna SC, Canário R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T. ESMO Open. 2023 Oct;8(5):101625. doi: 10.1016/j.esmoop.2023.101625. Epub 2023 Aug 31. PMID: 37659290 Free PMC article. No abstract available.

30.Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. PMID: 37525015 Free PMC article.

31.EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. Amaral T, Pop OT, Chatzioannou E, Sinnberg T, Niessner H, Zhao J, Ring SS, Joerger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch CM, Forschner A, Flatz L. J Am Acad Dermatol. 2023 Nov;89(5):1072-1074. doi: 10.1016/j.jaad.2023.06.057. Epub 2023 Jul 22. PMID: 37487833 No abstract available.

32.Prognosis in stage II melanoma of the head and neck depends on the histological subtype. Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A. J Dtsch Dermatol Ges. 2023 Oct;21(10):1137-1146. doi: 10.1111/ddg.15164. Epub 2023 Jul 23. PMID: 37485634

33.Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. Chatzioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuera LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. EBioMedicine. 2023 Jul;93:104644. doi: 10.1016/j.ebiom.2023.104644. Epub 2023 Jun 7. PMID: 37295047 Free PMC article.

34.Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. Gaißler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner NB, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. J Immunother Cancer. 2023 Jun;11(6):e006802. doi: 10.1136/jitc-2023-006802. PMID: 37286306 Free PMC article.

35.Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Nat Med. 2023 Jun;29(6):1310-1312. doi: 10.1038/s41591-023-02336-1. PMID: 37193799 No abstract available.

36.Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. Chatzioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez SS, Torres FM, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Am J Clin Dermatol. 2023 May;24(3):453-467. doi: 10.1007/s40257-023-00775-7. Epub 2023 May 4. PMID: 37142875 Free PMC article.

37.Reply to letter to the editor "Bureaucracy or Streamlining the Rules in "Good Clinical Practice (GCP)" - Has Equipoise Occurred?" by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna. Perez-Gracia JL, Penel N, Calvo E, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF. Ann Oncol. 2023 May;34(5):498-499. doi: 10.1016/j.annonc.2023.02.003. PMID: 37121610 No abstract available.

38.Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. Zarkavelis G, Amylidi AL, Verbaanderd C, Cherny NI, Metaxas Y, de Vries EGE, Zygoura P, Amaral T, Jordan K, Stribos M, Dafni U, Latino N, Galotti M, Lordick F, Giuliani R, Pignatti F, Pentheroudakis G. ESMO Open. 2023 Feb;8(1):100604. doi: 10.1016/j.esmoop.2022.100604. Epub 2022 Nov 14. PMID: 36870739 Free PMC article. Review.

39.Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Amaral T, Sinnberg T, Chatzioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S. Eur J Cancer. 2023 Mar;182:155-162. doi: 10.1016/j.ejca.2022.12.021. Epub 2022 Dec 30. PMID: 36739215

40.Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Nuñez NG, Berner F, Friebe E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzler L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper

N, Hölzel M, Power L, Kreutmaier S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joergers M, Früh M, Becher B, Flatz L. *Med.* 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. PMID: 36693381

41. Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer. Jordan K, De Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F. *Oncol Res Treat.* 2023;46(3):72-79. doi: 10.1159/000529128. Epub 2023 Jan 13. PMID: 36642069 Review.

42. Career and Professional Development for Young Oncologists. Mair MJ, Cardone C, Connolly L, Kfoury M, Lambertini M, Lim J, Mariamidze E, Matikas A, Pihlak R, Punie K, Oing C, Sánchez-Bayona R, Sobczuk P, Zhu H, Berghoff AS, Amaral T. *Oncol Res Treat.* 2023;46(3):67-71. doi: 10.1159/000528541. Epub 2022 Dec 6. PMID: 36473447 Review.

43. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akçetin L, Kölblinger P, Hoellwerth M, Meissner M, Mengi G, Braun AD, Mengoni M, Dummer R, Mangana J, Sindrilaru MA, Radmann D, Hafner C, Freund J, Rappersberger K, Wehsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler JM, Höller C, Eigentler T, Amaral T, Peitsch WK, Hillen U, Harth W, Ziller F, Schatten K, Gambichler T, Susok L, Maul LV, Läubli H, Debus D, Weishaupt C, Börger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen VA, Wanner M, Gutzmer R, Terheyden P, Kähler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune KM, Thoms KM, Heinzerling L, Heppert MV, Tratzmiller S, Hoetzenecker W, Öllinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posch C. *J Eur Acad Dermatol Venerol.* 2023 May;37(5):894-906. doi: 10.1111/jdv.18779. Epub 2022 Dec 12. PMID: 36433688

44. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials. Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G. *Ann Oncol.* 2023 Jan;34(1):70-77. doi: 10.1016/j.annonc.2022.09.162. Epub 2022 Oct 7. PMID: 36209982

45. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Gaißler A, Meldgaard TS, Heeke C, Babaei S, Tvingsholm SA, Bochem J, Spreuer J, Amaral T, Wagner NB, Klein R, Meier F, Garbe C, Eigentler TK, Pawelec G, Claassen M, Weide B, Hadrup SR, Wistuba-Hamprecht K. *Front Immunol.* 2022 Jul 7;13:906352. doi: 10.3389/fimmu.2022.906352. eCollection 2022. PMID: 35874702 Free PMC article.

46. Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. *EBioMedicine.* 2022 Aug;82:104143. doi: 10.1016/j.ebiom.2022.104143. Epub 2022 Jul 7. PMID: 35810563 Free PMC article.

47. Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy. Peisen F, Hänsch A, Hering A, Brendlin AS, Afat S, Nikolaou K, Gatidis S, Eigentler T, Amaral T, Moltz JH, Othman AE. *Cancers (Basel).* 2022 Jun 17;14(12):2992. doi: 10.3390/cancers14122992. PMID: 35740659 Free PMC article.

48. Zirkulierende Tumor-DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti-PD-1-Therapie. Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, Biskup S, Battke F. *J Dtsch Dermatol Ges.* 2022 Jun;20(6):867-871. doi: 10.1111/ddg.14766.g. PMID: 35711040 No abstract available.

49. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis CC, Ascierto PA, Eggermont AMM, Grob JJ, Hauschild A, Sekulovic LK, Long GV, Luke JJ, Michielin O, Peris K, Schadendorf D, Kirkwood JM, Lorigan PC; Central Malignant Melanoma Registry (CMMR). *J Clin Oncol.* 2022 Nov 10;40(32):3741-3749. doi: 10.1200/JCO.22.00202. Epub 2022 Jun 16. PMID: 35709414 Free PMC article.

50. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). *Eur J Cancer.* 2022 Jul;170:256-284. doi: 10.1016/j.ejca.2022.04.018. Epub 2022 May 24. PMID: 35623961 Review.

51. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). *Eur J Cancer.* 2022 Jul;170:236-255. doi: 10.1016/j.ejca.2022.03.008. Epub 2022 May 12. PMID: 35570085 Review.

52. Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy. Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, Biskup S, Battke F. *J Dtsch Dermatol Ges.* 2022 Jun;20(6):867-871. doi: 10.1111/ddg.14766. Epub 2022 May 12. PMID: 35555861 No abstract available.

53. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzhaim I, Eigentler T, Amaral T, Ossowski S, Rieß O, Flatz L, Garbe C, Forschner A. *J Cancer Res Clin Oncol.* 2023 Feb;149(2):833-840. doi: 10.1007/s00432-022-03939-w. Epub 2022 Feb 22. PMID: 35192052 Free PMC article.

54. The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series. Lim KHJ, Murali K, Thorne E, Punie K, Kamosioras K, Oing C, O'Connor M, Élez E, Amaral T, Garrido P, Lambertini M, Devnani B, Westphalen CB, Morgan G, Haanen JBAG, Hardy C, Banerjee S. *ESMO Open.* 2022 Feb;7(1):100374. doi: 10.1016/j.esmoop.2021.100374. Epub 2021 Dec 17. PMID: 35007996 Free PMC article.

55. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. Bochem J, Zelba H, Spreuer J, Amaral T, Wagner NB, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, Forchhammer S, Sinnberg T, Niessner H, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler TK, Löffler MW, Weide B, Wistuba-Hamprecht K. *J Immunother Cancer.* 2021 Dec;9(12):e003439. doi: 10.1136/jitc-2021-003439. PMID: 34933966 Free PMC article.

56. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Serna-Higueta LM, Amaral T, Forschner A, Leiter U, Flatz L, Seiber O, Thomas I, Garbe C, Eigentler TK, Martus P. *Cancers (Basel).* 2021 Dec 6;13(23):6141. doi: 10.3390/cancers13236141. PMID: 34885249 Free PMC article.

57. A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. Brendlin AS, Peisen F, Almansour H, Afat S, Eigentler T, Amaral T, Faby S, Calvarons AF, Nikolaou K, Othman AE. *J Immunother Cancer.* 2021 Nov;9(11):e003261. doi: 10.1136/jitc-2021-003261. PMID: 34795006 Free PMC article.

58. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany.

Keim U, Gandini S, Amaral T, Katalinic A, Hollecsek B, Flatz L, Leiter U, Whiteman D, Garbe C. Eur J Cancer. 2021 Dec;159:98-104. doi: 10.1016/j.ejca.2021.09.044. Epub 2021 Nov 3. PMID: 34742161

59.The ESSO core curriculum committee update on surgical oncology.
van der Hage J, Sandrucci S, Audisio R, Wyld L, Søreide K; ESSO core curriculum contributors; Amaral T, Audisio R, Bahadoor V, Beets G, Benstead K, Berge Nilsen E, Bol K, Brandl A, Braun J, Cufer T, Dopazo C, Edhemovic I, Eriksen JG, Fiore M, van Ginhoven T, Gonzalez-Moreno S, van der Hage J, Hutteman M, Masannat Y, Onesti EC, Rau B, De Reijke T, Rubio I, Ruurda J, Sandrucci S, Søreide K, Stattner S, Trapani D, D'Ugo D, Vriens M, Wyld L, Zahl Eriksson AG. Eur J Surg Oncol. 2021 Nov;47(11):e1-e30. doi: 10.1016/j.ejso.2021.10.003. Epub 2021 Oct 13. PMID: 34657781 Review.

60.The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II.
Lim KHJ, Murali K, Kamposioras K, Punie K, Oing C, O'Connor M, Thorne E, Amaral T, Garrido P, Lambertini M, Devnani B, Westphalen CB, Morgan G, Haanen JBAG, Hardy C, Banerjee S. ESMO Open. 2021 Aug;6(4):100199. doi: 10.1016/j.esmoop.2021.100199. Epub 2021 Jul 1. PMID: 34217129 Free PMC article.

61.Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.
Almansour H, Afat S, Serna-Higuita LM, Amaral T, Schraag A, Peisen F, Brendlin A, Seith F, Klumpp B, Eigentler TK, Othman AE. Acad Radiol. 2022 Apr;29(4):514-522. doi: 10.1016/j.acra.2021.04.015. Epub 2021 Jun 12. PMID: 34130924

62.Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036.
Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Hollecsek B, Martus P, Flatz L, Leiter U, Whiteman D. Eur J Cancer. 2021 Jul;152:18-25. doi: 10.1016/j.ejca.2021.04.029. Epub 2021 May 29. PMID: 34062483

63.Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Taberner J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. ESMO Open. 2021 Jun;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20. PMID: 33887690 Free PMC article. Review.

64.The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration.
Banerjee S, Lim KHJ, Murali K, Kamposioras K, Punie K, Oing C, O'Connor M, Thorne E, Devnani B, Lambertini M, Westphalen CB, Garrido P, Amaral T, Morgan G, Haanen JBAG, Hardy C. ESMO Open. 2021 Apr;6(2):100058. doi: 10.1016/j.esmoop.2021.100058. Epub 2021 Feb 4. PMID: 33601295 Free PMC article.

65.Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R, Capone M, Giannarelli D, Morretta E, Monti MC, Madonna G, Mallardo D, Festino L, Azzaro R, Levesque MP, Imhof L, Weide B, Amaral T, Chevrier M, Sucker A, Rutkowski P, Schadendorf D, Lebbe C, Luke JJ, Wistuba-Hamprecht K, Dummer R, Pinto A, Morello S, Ascierto PA. J Immunother Cancer. 2020 Dec;8(2):e001689. doi: 10.1136/jitc-2020-001689. PMID: 33361405 Free PMC article.

66.An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.
Amaral T, Niessner H, Sinnberg T, Thomas I, Meiwes A, Garbe C, Garzarolli M, Rauschenberg R, Eigentler T, Meier F. Neurooncol Adv. 2020 Oct 22;2(1):vdaa140. doi: 10.1093/oaajnl/vdaa140. eCollection 2020 Jan-Dec. PMID: 33305271 Free PMC article.

67.Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.
Gambichler T, Tsagoudis K, Kiecker F, Reinhold U, Stockfleth E, Hamscho R, Egberts F, Hauschild A, Amaral T, Garbe C. Eur J Cancer. 2021 Jan;143:11-18. doi: 10.1016/j.ejca.2020.10.016. Epub 2020 Dec 2. PMID: 33278769

68.Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Hilke FJ, Sinnberg T, Gschwind A, Niessner H, Demidov G, Amaral T, Ossowski S, Bonzheim I, Röcken M, Riess O, Garbe C, Schroeder C, Forschner A. Cancers (Basel). 2020 Aug 20;12(9):2359. doi: 10.3390/cancers12092359. PMID: 32825510 Free PMC article.

69.Adjuvant and neoadjuvant therapies in melanoma.
Lim KHJ, Amaral T. ESMO Open. 2020 Jul;5(4):e000849. doi: 10.1136/esmoopen-2020-000849. PMID: 32616511 Free PMC article.

70.Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM; German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2020 Aug 1;38(22):2543-2551. doi: 10.1200/JCO.19.03034. Epub 2020 Jun 12. PMID: 32530760 Free PMC article.

71.Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase.
Glutsch V, Amaral T, Garbe C, Thoms KM, Mohr P, Hauschild A, Schilling B. Acta Derm Venereol. 2020 Jun 11;100(13):adv00174. doi: 10.2340/00015555-3526. PMID: 32449784 Free PMC article.

72.ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.
Perez-Gracia JL, Awada A, Calvo E, Amaral T, Arkenau HT, Gruenwald V, Bodoky G, Lolkema MP, Di Nicola M, Penel N, Vera R, Sanmamed MF, Douillard JY. ESMO Open. 2020 May;5(3):e000662. doi: 10.1136/esmoopen-2019-000662. PMID: 32393574 Free PMC article. Review.

73.Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, Biskup S, Forschner A. Cancers (Basel). 2020 Apr 28;12(5):1101. doi: 10.3390/cancers12051101. PMID: 32354124 Free PMC article.

74.Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.
Amaral T, Seeber O, Mersi E, Sanchez S, Thomas I, Meiwes A, Forschner A, Leiter U, Eigentler T, Keim U, Garbe C. Cancers (Basel). 2020 Apr 22;12(4):1027. doi: 10.3390/cancers12041027. PMID: 32331243 Free PMC article.

75.S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ - Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Prävention und Berufskrankheit.
Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberger C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C. J Dtsch Dermatol Ges. 2020 Apr;18(4):400-413. doi: 10.1111/ddg.14072_g. PMID: 32291932 German.

76.S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease.
Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberger C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C. J Dtsch Dermatol Ges. 2020 Apr;18(4):400-413. doi: 10.1111/ddg.14072. Epub 2020 Apr 4. PMID: 32247292

77. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pföhler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tuetting T, Heinrich V, Eigentler T, Garbe C, Zimmer L; *German Dermatological Cooperative Oncology Group. *J Immunother Cancer*. 2020 Mar;8(1):e000333. doi: 10.1136/jitc-2019-000333. PMID: 32221017 Free PMC article.

78. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators.
Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberger C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C.
J Dtsch Dermatol Ges. 2020 Mar;18(3):275-294. doi: 10.1111/ddg.14048. PMID: 32130773

79. S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ - Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitätsindikatoren.
Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberger C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C.
J Dtsch Dermatol Ges. 2020 Mar;18(3):275-294. doi: 10.1111/ddg.14048_g. PMID: 32130769 German.

80. MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.
Forschner A, Hilke FJ, Bonzheim I, Gschwind A, Demidov G, Amaral T, Ossowski S, Riess O, Schroeder C, Martus P, Klumpp B, Gonzalez-Menendez I, Garbe C, Niessner H, Sinnberg T. *Cancers (Basel)*. 2020 Feb 26;12(3):540. doi: 10.3390/cancers12030540. PMID: 32110946 Free PMC article.

81. Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry.
Sarac E, Amaral T, Keim U, Leiter U, Forschner A, Eigentler TK, Garbe C.
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2021-2025. doi: 10.1111/jdv.16306. Epub 2020 Mar 30. PMID: 32078189

82. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).
Eur J Cancer. 2020 Feb;126:141-158. doi: 10.1016/j.ejca.2019.11.014. Epub 2020 Jan 9. PMID: 31928887

83. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).
Eur J Cancer. 2020 Feb;126:159-177. doi: 10.1016/j.ejca.2019.11.015. Epub 2019 Dec 19. PMID: 31866016

84. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
Amaral TMS, Hoffmann MC, Sinnberg T, Niessner H, Sülberg H, Eigentler TK, Garbe C. *Eur J Cancer*. 2020 Jan;125:38-45. doi: 10.1016/j.ejca.2019.10.027. Epub 2019 Dec 12. PMID: 31838403

85. Late recurrence of melanoma after 10 years - Is the course of the disease different from early recurrences?
Sarac E, Wilhelmi J, Thomas I, Leiter U, Keim U, Eigentler TK, Garbe C, Amaral T. *J Eur Acad Dermatol Venereol*. 2020 May;34(5):977-983. doi: 10.1111/jdv.16106. Epub 2019 Dec 18. PMID: 31758713

86. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C. *J Immunother Cancer*. 2019 Nov 13;7(1):299. doi: 10.1186/s40425-019-0800-0. PMID: 31722735 Free PMC article.

87. Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns.
Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U.
J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:44-51. doi: 10.1111/jdv.15845. Epub 2019 Oct 28. PMID: 31658392

88. Targeting tumor-resident mast cells for effective anti-melanoma immune responses.
Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T. *JCI Insight*. 2019 Oct 3;4(19):e125057. doi: 10.1172/jci.insight.125057. PMID: 31578309 Free PMC article.

89. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigentler T, Wagner NB, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K.
PLoS One. 2019 Aug 16;14(8):e0221301. doi: 10.1371/journal.pone.0221301. eCollection 2019. PMID: 31419253 Free PMC article.

90. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S. *J Immunother Cancer*. 2019 Jul 12;7(1):180. doi: 10.1186/s40425-019-0659-0. PMID: 31300034 Free PMC article. Clinical Trial.

91. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.
Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A. *Immunotherapy*. 2019 Mar;11(4):297-309. doi: 10.2217/imt-2018-0149. Epub 2019 Jan 4. PMID: 30606066

92. Time trends in incidence and mortality of cutaneous melanoma in Germany.
Garbe C, Keim U, Eigentler TK, Amaral T, Katalinic A, Holleczek B, Martus P, Leiter U. *J Eur Acad Dermatol Venereol*. 2019 Jul;33(7):1272-1280. doi: 10.1111/jdv.15322. Epub 2019 Apr 17. PMID: 30387899

93. How to use neoadjuvant medical treatment to maximize surgery in melanoma.
Amaral T, Tampouri I, Garbe C. *Expert Rev Anticancer Ther*. 2018 Feb;18(2):121-130. doi: 10.1080/14737140.2018.1421460. Epub 2018 Jan 3. PMID: 29271674 Review.

94. Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.
Amaral T, Leiter U, Garbe C. *Rev Endocr Metab Disord*. 2017 Dec;18(4):517-532. doi: 10.1007/s11154-017-9433-0. PMID: 28916903 Review.

95. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T, Meraz-Torres F, Garbe C. *Expert Opin Biol Ther*. 2017 Dec;17(12):1523-1538. doi: 10.1080/14712598.2017.1378640. Epub 2017 Sep 17. PMID: 28891339 Review.

96. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
Spänkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T. *Eur J Cancer*. 2017 Aug;81:203-205. doi: 10.1016/j.ejca.2017.05.018. Epub 2017 Jun 20. PMID: 28641200 No abstract available.

97. Non-melanoma skin cancer: new and future synthetic drug treatments.
Amaral T, Garbe C.

Expert Opin Pharmacother. 2017 May;18(7):689-699. doi: 10.1080/14656566.2017.1316372. Epub 2017 Apr 17. PMID: 28414587 Review.

98.The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.
Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3. PMID: 28169047 Review.

99.Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. PMID: 28255451 Free PMC article. Review.

100.MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.
Eur J Cancer. 2017 Mar;73:93-101. doi: 10.1016/j.ejca.2016.12.012. Epub 2017 Feb 3. PMID: 28162869 Review.

101.Acquired resistance mechanisms to immunotherapy.
Amaral T, Garbe C. Ann Transl Med. 2016 Dec;4(24):547. doi: 10.21037/atm.2016.12.21. PMID: 28149908 Free PMC article. No abstract available.

102.Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK.
J Cancer Res Clin Oncol. 2017 Mar;143(3):533-540. doi: 10.1007/s00432-016-2309-y. Epub 2016 Nov 22. PMID: 27878363

103.The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T, Nouri N, Garbe C. Expert Rev Anticancer Ther. 2016 Jul;16(7):705-15. doi: 10.1080/14737140.2016.1192469. Epub 2016 Jun 10. PMID: 27219630 Review.

Projects

see CV

Memberships

Awards

2024 ASCO Conquer Cancer Merit award
2022 ASCO Conquer Cancer Merit award
2020 1st MAYA (Melanoma Award for Young Academics) - Novartis
2006 Award Portuguese Air Force Academy: "Chefe de Estado Maior da Força Aérea – 2006-2007" – Portuguese Air Force Academy
2005 Award: "Spadino Dell'Academia Aeronautica – Il Capo di Stato Maggiore dell'Areronautica Millitare Itlaiana – 2004-2005"
2004 Award: "Adido de Defesa e Aeronáutico Dos Estados Unidos da América 2003-2004" – Portuguese Air Force Academy

Other activities

2023-current Nominated - Subject editor European Society of Medical Oncology (ESMO) clinical practice guidelines for melanoma & other skin cancers
2023-current Nominated - Chair of the ESMO Leadership development committee
2021-current Nominated - Mentor from the ESMO YOC virtual mentorship program
2020-2023 Elected and Nominated - Chair of the ESMO Young Oncologists Comittee (YOC)
2020-2022 By invitation - Member of the ESMO social media WG
2019-current By invitation - ESMO faculty member for the Melanoma faculty
2019-2022 By invitation - Member of the ESMO clinical research observatory (ECRO) task force
2019-current By invitation - Member of the ESMO magnitude of clinical benefit scale (ESMO-MCBS) working group
2019 By competitive selection - Allumna of the ESMO Leaders Generation Program (LGP)
2018-2022 Elected and Nominated - Member of the Portuguese Young Oncologists Group
2010- current External Clinical Expert for INFARMED – Portugal in the area of solid tumor

Other Relevant Information

see Cv